Adria Cimino

Adria Cimino


Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter.

Recent articles


2 Healthcare Stocks to Buy in 2021 and Hold for the Next Decade

If you sell too quickly, you'll miss out on billions of dollars in product revenue -- and share performance.


My Top 3 Large-Cap Stocks to Own in 2021

Dividends and increasing revenue mean you can count on these companies for safety and growth.


2 Stocks That Could Turn Your $600 Stimulus Check Into a Fortune

Their winning streaks aren't over just yet.


My Best Coronavirus Vaccine Stock for 2021

Can this winner keep on succeeding?


The Top 3 Biotech Stocks to Buy in 2021

Revenue growth is just beginning for these companies.


Where to Invest $100,000 Right Now

The key is diversification -- and a focus on companies showing strength today and promise of long-term growth.


2 Under-the-Radar COVID Vaccine Stocks to Buy for 2021

Transport and storage of their potential vaccines would be a piece of cake.


3 Reasons Why Teladoc Stock Has Potential to Climb in 2021

Virtual healthcare visits are here to stay.


3 Things to Expect from Novavax in 2021

This may be the year of revenue.


Did You Miss Out on the Chance for Big Gains from Arcturus Stock?

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.


2 Coronavirus Stocks That Will Keep Winning in 2021

The U.S. is focusing on coronavirus testing and vaccination. And that's exactly where these companies excel.


Why Your 2021 Resolution Should Be to Buy More Cruise Stocks

The coronavirus outbreak sank their profits. But hope is on the horizon.


2 Best Robinhood Stocks to Buy for 2021

These companies are heading into a new phase of growth.


If You Invested $1,000 in Novavax in January, This Is How Much Money You'd Have Now

The biotech's gains in 2020 were stellar. Heading into 2021, can investors expect more share price appreciation?


Worried Coronavirus Will Last Through 2021? Buy These 3 Stocks Now

These companies weathered the worst of the coronavirus storm -- and are ready for what appears to be the next phase.


Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

Cost and logistics will determine the ultimate winner.


The 3 Best Stocks for 2021

A beaten-down biotech, a streaming star, and a coronavirus testing giant could be well-rounded additions to your portfolio.


Better Buy: Nike vs. Target

They both are 2020's retail winners. But one may have an easier time of it in the coming months.


Is There Still Room for Growth for These 2 Coronavirus Stocks?

They are at a critical point. What happens next could push them higher, or result in a big loss.


The Smartest Investors Bought This Stock in 2020

Buying this "stay-at-home" stock was the right strategy.